-
Why Amgen's Stock Is Trading Higher Today
Wednesday, July 1, 2020 - 3:31pm | 164Read More...Amgen (NASDAQ: AMGN) shares are trading higher on Wednesday after an appeals court confirmed the validity of its Enbrel patents. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Its flagship drugs...
-
Amgen Stock Falls After 'Boring' Q3 Beat
Thursday, October 26, 2017 - 10:49am | 449Read More...Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...
-
'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts
Wednesday, July 26, 2017 - 4:33pm | 622Read More...Amgen, Inc. (NASDAQ: AMGN) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst M. Ian Somaiya downgraded Amgen's stock rating from Outperform to Market Perform...
-
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Wednesday, January 18, 2017 - 11:40am | 453Read More...Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...
-
The 5 Top-Selling Drugs In The World
Tuesday, September 20, 2016 - 12:09pm | 488Read More...The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...
-
Barclays Says Acceleration For Amgen Could Be A Challenge
Thursday, July 28, 2016 - 11:18am | 432Read More...Amgen, Inc. (NASDAQ: AMGN) reported robust 2Q results on both the top and bottom lines, modestly beating expectations. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $185. Further Acceleration Could Be Challenging “While we have fairly...
-
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Wednesday, June 29, 2016 - 1:56pm | 242Read More...Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...
-
What Are The Best-Selling Drugs Of 2014?
Friday, October 3, 2014 - 11:34am | 759Read More...What are the top-selling pharmaceutical drugs of the year? While 2014 is not yet over, it's possible to explore to answer to this question after making a few educated assumptions. According to research from IMS Health, a healthcare services, information and technology provider, the top...
